Internal Medicine Principal Investigator
Resume:
Akavaram N . Reddy
M . D . F. A . C . R
C AREER
EDUCATION &
TRAINING
University of Louisville School of Medicine, Louisville, KY Rheumatology Fellowship (1979 – 1981)
Wright State University, V.A. Hospital, Dayton, OH Chief Medical Resident (1978-1979)
Internal Medicine Residency (1976-1979)
Resurrection Hospital (Loyola University), Chicago, IL Rotating Internship (1975-1976)
Kakatiya Medical School, Warangal, A.P. India
Osmania University (1973)
PUBLICATIONS
State of Maine - Active
M E D I C A L
L I C E N SES —
State of Idaho - Active
State of Florida - Active
“Empyema caused by Clostridum Perfringens.”
by Reddy, Akavaram, et al, Journal of Kentucky Medical Association
(July 1980)
“Neuromuscular Disorders in Thyrotoxcosis.”
by Ali & Akavaram, American Family Physician (September 1980)
“Cimetidine Induced Leukopenia.”
by Khokar, N. & Akavaram Reddy, Military Medicine (December 1980)
“Changes in Lymphocyte Responsiveness to Mitogen Stimulation in Patients with Rheumatoid Arthritis (RA) treated with Gold.” by Cummings, N. Cherian S., Reddy, A (Abstract- Accepted by the American Rheumatism Association).
“Lipoid Nephrosis in the Elderly.”
by N. Khokhar, N.R. Akavaram, Em Quinones
South Med J. 1980, Jun; 73(6):7.90-1
POSITION S H E L D
Chief of Rheumatology
St. Vincent’s Medical Center
Jax (1982 - 2002)
—
[ References Available
Upon Request ]
—
C E R T I F I C A T I O N S —
American Board of Internal
(1980 - Present)
American Board of
Rheumatology (1982 - Present)
Founding Fe llow
Ameri can C olle g e
o f R h e u matology
8216 Hunters Grove Rd.
Jacksonville, FL 32256
*********@*****.***
Arthritis and Rehab Center of Jacksonville
Jacksonville, FL
Rheumatology, Private Practice (1981-2006)
Waldo County General Hospital
Belfast, ME
Locums (April 2024 September 2024)
Arthritis Center of Idaho, PA
Twin Falls, ID
Physician, St. Lukes Rheumatology (2006 – 2023)
Minidoka Memorial Hospital
Rupert, ID
Employment Part-time (May 2024 - Present)
“Double-Blind, placebo-Controlled Evaluation of The Safety and Efficacy of Three Doses of Topically Applied Ketoprofen Transfersome Gel (KTG) in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of OA of the Knee.”
(McNeil) August 2005 - Ongoing Principal Investigator.
“Double-Blind, Randomized, Placebo-Controlled, Phase III, Efficacy and Safety Study of Tramadol ER 300mg, Taken Once-Daily for The Management of Moderate to Moderately Severe Chronic Pain in Osteoarthritis of the Hip and Knee.”
(Cipher) April 2004 - October 2005 Principal Investigator.
“Randomized, Multicenter, Double-Blind, Double Dummy Study Comparing the Efficacy and Tolerability of Once Daily Celebrex (celecoxib) and Naproxen 500mg Twice Daily in the 6month Treatment of Subjects with OA of the Knee.”
(Pfizer) December 2003 - March 2005 Principal Investigator.
“Double-Blind, placebo Controlled, Comparative of the Efficacy and Safety of Bextra 10mg Once Daily and Naproxen 500mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population.”
(Pfizer) May 2003 - January 2005 Principal Investigator.
“Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study.”
(IMMUNEX) October 2001 - March 2005 Principal Investigator.
“Randomized, Double-Blind, Phase III Study, Comparing the Efficacy and Safety of Lansoprazole 30mg QD and Naproxen 500mg BID Versus Celecoxib 200mg QD in Risk Reduction of Non Steroi- dal Anti-Inflammatory Associated Ulcers in OA Subjects taking low dose aspirin.”
(TAP Pharm.) June 2003 - June 2004 Principal Investigator.
“Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg QD and 20mg QD) Versus Placebo for the Prevention of Gastric Ulcers Associated with Daily NSAID Use in Patients at Risk.”
(Astra Zeneca) November 2001 - June 2003 Principal Investigator.
“A Multi-Center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Eficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5) and Placebo in Patients with Rheumatoid Arthritis.”
(Astra Zeneca) July 2002 - August 2003 Principal Investigator.
“A Double-Blind, placebo Controlled, Randomized Two Week Comparison Study of The Efficacy and Tolerability of Valdecoxib 10mg QD and Rofecoxib 25mg in Treating the Signs and Symp- toms of Osteoarthritis of the Knee.”
(Pharmacia) July 2002 - June 2003. Principal Investigator.
“A Phase II Randomized, Multicenter Study Comparing the Safety and Efficacy of Orat TMX67 versus Allopurinol in Subjects with Cour.”
(Pharmacia) July 2012 March 2003 Principal Investigator.
“Open Label, Crossover Study to Assess Acceptability and Functionality of Simpleject Versus Pre-filled Syringes(s) When Administered Şubcutaneous (SC) Using Kineret (anakinra) in Rheu- matoid Arthritis Subjects.”
(Amgen) December 2002 May 2003 Principal Investigator.
“Double-Blind, Randomized Three Arm, Two Period, Crossover Study to Compare Celecoxib, Acetaminophen, and Placebo in Patients with Osteoarthritis of the Hip or Knee.”
(Pharmacia) October 2001 - August 2003 Principal Investigator. CLINICAL RESEARCH
“A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCL Once A Day 100mg, 200mg, and 300mg, Versus Placebo For the Treatment of Pain due to Osteoarthritis of the Knee.” (Biovail Lab.) January 2002 - July 2003. Principal Investigator.
“Multi-Center, Randomized, Double-Blind, Multiple Dose Assessment of The Efficacy of Celecox- ib 200mg QD, and 400mg QD, Naproxen 500mg BID, and Placebo in Patients with Ankylosing Spondylitis.” (Pharmacia) November 2001 November 2003 Principal Investigator.
“Clinical Protocol for the Efficacy of Treatment by Celecoxib 200mg QD and 400mg QD for the Symptoms of Ankylosing Spondylitis Compared to Naproxen 500mg QD and Placebo.”
(Pharmacia) October 2001 - July 2003 Principal Investigator.
“A Long-Term, Observational Study of Disease Progression and Treatment in Patients with New Onset Rheumatoid Arthritis.” (Knoll) July 2000 - July 2003 Principal Investigator.
“Double-Blind, placebo Controlled, Randomized Six Week Comparison Study of The Efficacy of Valdecoxib 20mg QD and Rocefecoxib 25mg QD in Relieving the Signs and Symptoms of Osteo- arthritis of the Knee.” (Pharmacia) August 2001-November 2001 Principal Investigator.
“Double-Blind, placebo Randomized Six Week Comparison of the Efficacy and Safety of Celecox- ib 200mg QD and Rofecoxib 25mg QD in Relieving the Signs and Symptoms of Osteoarthritis of the Knee.” (Pharmacia) May 2001 - July 2001. Principal Investigator.
“A Multi-Center, Randomized, Double-Blind, placebo-Controlled Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Patients with Active Rheumatoid Arthritis.” (Knoll) June 2000 - June 2001 Principal Investigator.
“An Active-Comparator and Placebo-Controlled, Paralled Group, Double-Blind, 52 Week Study to Assess the Safety and Efficacy of MK-0663 in Rheumatoid Arthritis Patients.”
(Merck) October 1999 - May 2001 Principal Investigator.
“Clinical Protocol to Evaluate the Long-Term Safety of Valdecoxib in Treating the Signs and Symptoms of Rheumatoid Arthritis.”
(SEARLE) December 1999 May 2001 Principal Investigator
“Multi-Center, Double-Blind, Parallel Group Study Comparing the Effects on the Renal Function and the Incidence of the Gastro duodenal Ulcer associated with Valdecoxib 20mg and 40mg BID with Valdecoxib 20mg and 40mg BID with Naproxen 500mg BID in Patients with Osteo- arthritis or Rheumatoid Arthritis.” (SEARLE) October 1999 - April 2001 Principal Investigator.
“Double-Blind, placebo, Randomized Six Week Comparison Study of the Efficacy of Celecoxib 200mg QD and Rofecoxib 25mg QD in Relieving the Signs and Symptoms of OA of the Knee.”
(SEARLE) February 2000 - June 2000 Principal Investigator.
“Double-Blind, Randomized, Stratiied, Parallel-Group Study to Assess the Incidence of PUB's During Chronic treatment with MK-0966 or Naproxen in Patients with Rheumatoid Arthritis.”
(Merck) January 1999 - February 2000 Principal Investigator.
“Clinical Protocol to Evaluate the Long-Term Safety of Valdecoxib in treating the Signs and Symptoms of Rheumatoid Arthritis.”
(SEARLE) September 1998 - December 1999 Principal Investigator.
“Double-Blind, Randomized, Placebo-Controlled Study of GW-80126 at 1500mg and 2250mg QD in Patients with RA after Withdrawal from NSAID Therapy.”
(Greenwich Pharm) December 1992 - December 1993 Principal Investigator.
“Clinical Protocol to Evaluate the Long-Term Safety of Valdecoxib 40mg BID in Patients with Osteoarthritis or Rheumatoid Arthritis.” (SEARLE) April 1991-August 1992 Principal Investigator. CLINICAL RESEARCH
Contact this candidate